MercachemSyncom has acquired Admescope. The acquisition will give MercachemSyncom expanded capabilities for tailor-made in vitro and in vivo ADME-Tox studies for preclinical and early clinical R&D projects and integration with the existing medicinal, synthetic and development chemistry capabilities of MercachemSyncom.
Admescope was founded in Oulu, Finland in 2011, and currently employs 40 scientists. The scientific and management teams have experience in tailored ADME-Tox studies for pharma and biotech clients all over the world. Studies are carried out at research laboratories in both Oulu and Södertälje, Sweden with emphasis on customers' needs, in-house processes and how to design the most effective studies to satisfy them.
Eelco Ebbers, CEO of MercachemSyncom, commented: “We are extremely happy to be able to welcome our colleagues at Admescope to MercachemSyncom. MercachemSyncom is at the forefront of a continuing consolidation of high-quality contract research and manufacturing organizations into medium-sized, but still agile, companies able to offer an extended palette of R&D services to long-standing and new clients.”
Ari Tolonen, CEO of Admescope, added, "We are thrilled to continue our successful growth as a part of MercachemSyncom. We feel that the cultural fit between our companies is excellent, and with the support of MercachemSyncom we will be able to continue meeting and exceeding our customers’ expectations for contract research services. Our customers will benefit from the extensive integrated discovery and development service offering that we will provide together with our new colleagues at MercachemSyncom.
”The whole Admescope team is excited to get to work with our new international colleagues, and we are confident that our customers will benefit from this collaboration and its impact to the services that they have grown fond of over the years of working with us."
